This review is an attempt to bring together the pharmacokinetic data on d-tubocurarine and pancuronium with clinical observations on relaxant dosage and effect. The modelling techniques used here represent an oversimplification of the relationships between relaxant plasma concentration and response as they do not predict either the time of onset of paralysis or its peak intensity. However, they do enable calculation of a bolus dose of relaxant required to achieve a particular intensity of paralysis for the average patient once pseudo-distribution equilibrium has been achieved. This has been further extended to predict the cumulation of the relaxants with subsequent dosage in average patients. Suggested regimens incorporating bolus and infusion doses of the relaxants to achieve continuous neuromuscular blockade have been calculated also. Averaged pharmacokinetic parameters derived from patients with renal or hepatic dysfunction have been used to predict the likely duration and intensities of paralysis for the relaxants.
Pharmacokinetics is the quantitative study of drug and drug metabolite disposition in the body.
An increasing number of pharmacokinetic publications in the medical literature has prompted several workers to review the topic for the practising clinician as an aid to the more rational use of drugs. I -3 "The rational use of drugs and the design of effective dosage regimens is facilitated by an appreciation of the relationship between drug concentration in a readily accessible body compartment (usually the central compartment which includes blood plasma) and the intensity of pharmacologic effects."4 With the neuromuscular blocking agents these effects may be graded from zero to 100 per cent paralysis. Recent developments in drug assay techniques allow characterisation of these effects by relating them to both the administered dose and drug concentration in the plasma.
This review attempts to demonstrate the use of pharmacokinetics in the more rational use of muscle relaxants by the anaesthetist by bringing together many of the dosage and response data for d-tubocurarine (dTc) and pancuronium (Pc) and relating them to the disposition kinetics of the two relaxants.
Assumption and definitions
A number of assumptions and definitions have been used throughout this review: 1. The pharmacokinetics of both dTc and Pc have been assumed to be adequately described by a two compartment open model. This assumption has been found to be satisfactory in the several studies carried out in our laboratories. 5 -1O 2. In clinically useful doses, there is a definable relationship between the total Anaesthesia and Intensive Care, Vol. VIII, No. I, February, 1980 measured plasma concentration of the relaxant during the offset of effect and the intensity of paralysis as measured at the hand. 3. The early relative potencies of the two drugs (dTc and Pc) can be calculated from the ratios of the bolus and infusion doses required to produce the same intensity of effect (per cent paralysis). Further, the size of the bolus doses may be calculated by the product of the desired plasma concentration of relaxant required for a particular degree of paralysis and the appropriate volume of distribution term for the drug. Such calculations assume that the volume of the distribution of the drug remains constant and independent of dose. 4. Late relative potencies can be compared using the ratio of drug requirements for maintenance of paralysis when the relaxants are administered by the bolus and infusionY Further, these infusion rates can be calculated by the product of the desired plasma concentration of relaxant with its plasma clearance. 5. Data reported for normal subjects on the basis of body surface area may be converted to values based on body weight by multiplication by a factor of 1.75 (m2) for a 70 kg patient. 6. The presence of halothane or other potent inhalation agents produces a "shift to the left" of both the dose-response and the plasma concentration curves. 12 This also holds true for an increase in the frequency of the applied stimulation. If results at one pulse per 10 sec. The plasma concentration-time curves for dTc and for Pc in man have been examined in many pharmacokinetic studies, and the results fitted to a two-(or three-) compartment open model which may be described mathematically by equation 1:
where Cp(t) is the plasma concentration of the relaxant at time t after an intravenous bolus injection, A, B, C are the coefficients and a, {3, y are the exponents (a > (3 > y) of the appropriate equation.
If the two-compartment open model is adopted, then the plasma concentration-time data following multiple dose administrations may be described by equation 2, using appropriate adjustments for successive doses and times of administration: (1) where k21 represents an intercompartmental transfer rate constant, a and {3 are hybrid rate constants, V is the reciprocal value of the volume of the central compartment (ml), D is the dose (J.tg) and N is the number of doses. Pharmacokinetic data for dTc and Pc in 70 patients from various studies carried out in our laboratories were pooled and the results are shown in Table 1 . 
Drug concentration, onset, intensity and duration of effect
The disposition of dTc and Pc in humans has been investigated chiefly by measuring drug concentrations in plasma. However, the plasma concentration is a poor predictor of neuromuscular paralysis during the onset of paralysis as these concentrations are measured when distribution of the drug between the various tissues in the body is not complete. Thus, there is no direct relationship between the measured plasma concentration and the concentration (or amount) of drug at the site of action which is presumably proportional to the observed pharmacologic response. There is a distinct time lag between administration and the onset of pharmacological effect even though plasma concentrations of the relaxant are high (in the case of a bolus IV dose) and models which include an explanation for this phenomenon have been presented for PC 17 and for dTd 8 • During the late (terminal) phase of drug disappearance from the plasma Matteo et al. 19 reported a linear relationship between the plasma concentration of dTc and the degree of neuromuscular paralysis. Feldman 20 disagreed with Matteo and suggested that what Matteo had demonstrated was that following injection of dTc the serum levels of the drug in similar individuals fall at approximately the same rate, and that the coincident recovery of neuromuscular blockade also occurs at similar rates in different individuals. Waud,21 however, concluded that the observations of Matteo and co-workers and Feldman were not in disagreement with each other or with the conventional view of neuromuscular physiology and pharmacology.
While the review which follows largely ignores the controversy surrounding the relationship between the plasma concentration of the relaxant and the pharmacologic effect it must be remembered that the data presented here is averaged, often from different series of publications with a wide scatter of results, and may thus be inappropriate for a particular patient. Katz 22 has stated that the response of different patients to specific doses of dTc varies over a wide range.
Relationship between muscle relaxant-receptor dissociation constant (K B ), drug concentration and response
The degree of receptor occlusion associated with various intensities of neuromuscular block has been estimated experimentally.23.13-15 Some of the results from the excellent review of Waud and Waud 24 are summarized in Table 2 . It should be noted from Table 2 that going from minimal to complete peripheral block results in an approximate trebling of the agonist concentration. Also apparent from the table is that for diaphragmatic paralysis one needs double the agonist concentration required to block peripheral muscle. Relationship between receptor occlusion, against concentration and levels of neuromuscular block (after Waud and Waud, 1975 24 ) . In Table 2 , the concentration of agonist required to block a particular fraction of receptors (to produce a particular degree of paralysis) is expressed relative to K B , the drugreceptor dissociation constant. A value for KB has not been determined in man, but experiments with guinea pigs' lumbrical muscle have provided a value of approximately 0.lO7 J-tM for dTc and 0.025 J-tM for PC 24 (see Table 4 ). To relate the in vitro agonist concentrations reported in Table 2 to in vivo concentrations of dTc and Pc in man one needs to consider steady state concentrations of the relaxants corresponding to a particular degree of receptor occlusion or neuromuscular paralysis. Such steady state concentrations are needed since at this time no disequilibrium between the various sites is possible, and a constant proportionality between plasma concentration and active site Anaesthesia and Intensive Care, Vol. VIII, No. 1, February, 1980 concentration is present. Unfortunately there is little data available in man for steady state concentrations of the relaxants at 95 per cent paralysis. There are however, studies in which the total plasma concentrations of these relaxants have been measured during offset of paralysis. Such concentrations have been measured under non steady state conditions and are likely to be underestimates of the true steady state values. Some of these concentrations corresponding to 95 per cent paralysis are presented in Table 3 . It should be emphasised also that the chemical assay techniques which provided the results shown in Table 3 give the total concentration of drug in plasma, both protein bound and free drug. In the case of Pc it could include also levels of the metabolite in plasma. Equating the agonist concentration presented in Table 2 to the in vivo plasma concentrations of the two relaxants given in Table 3 allows calculation of the free drug concentration corresponding to a particular degree of neuromuscular paralysis. This is performed using the in vitro value for KB and using the relationship: this degree of paralysis (from Table 3 ) allowed estimation of the amount of drug bound to plasma protein (see also 25 at a dTc concentration of 5 Ilg/ml, when one considers that these calculations were based on non steady state values. Ramzan et al. 9 reported a steady state concentration of dTc of 1.09Ilg/ml corresponding to 95 per cent paralysis, and if this value for the total concentration of dTc is used then a value of 45 per cent for the degree of binding of dTc to plasma protein is obtained.
The degree of plasma protein binding of Pc is less clear. Waser 6 has reported a value of 20 per cent, while Thompson 27 stated that less than 13 per cent of a dose in the clinical range would be present as free, active drug. Thompson, however, examined Pc binding to individual plasma protein fractions but not in whole plasma. 
Disappearance of the relaxantsfrom the plasma and decline of effect
Levy28 described the theoretical relationship between the rate of elimination of dTc from the plasma and the rate of decline of its pharmacological activity. He assumed that the intensity of its effect was proportional to the logarithm of the dose, and showed a basis for an exponential decrease in drug concentration and a linear decrease in activity. In 1972 Gibaldi and Levy29 examined data for both dTc and Pc and described an equation relating the rate of decline of paralysis and the apparent rate of decline of the plasma concentrations in the 20 to 80 per cent response range.
In 1978 we reported plasma concentrationresponse relationships during and following Pc infusion. 6 The data was fitted to an equation for a sigmoid curve:
100% . Cps 070 paralysis ECplOS + cps
where Cp is the plasma concentration, ECp50 is the mean effective plasma concentration at 50 per cent paralysis, and s is a power function. This procedure may be used to describe the response-concentration relationship for the whole (0 to 100 per cent) response range. Composite curves for Pc and dTc have now been reported,lO and the values for best fit to the sigmoid equation are shown in Table 5 .
Since this equation gives the degree of paralysis for any given plasma concentration, it can be used to predict the time for recovery from paralysis following single or multiple administrations of relaxants, where the plasma concentration (Cp) at a particular time is given by either equation 1 or equation 2 respectively. Table 1 gives some of the pharmacokinetic parameters for dTc and Pc in normal patients. The apparent volume of distribution (VdfJ) and the plasma clearance (CLp) terms can be utilised in association with the desired steady state plasma concentration of the relaxant (CPss) to determine the size of the bolus and infusion doses required to provide a sustained level of neuromuscular paralysis such as may be needed for prolonged surgical procedures. The bolus dose may be calculated from: Equation 3 Bolus dose = Vd~. cPss and the infusion rate by: Equation 4 Infusion rate = CLp . cPss These equations were used in calculating the data appearing in Table 6 , assuming the adequacy of the non-steady state plasma concentration to produce 95 per cent paralysis (C 95) at 0.1 Hz ( Table 3 ). The dTc values in Table 6 are very close to those used in a dTc bolus and infusion study,9 where the C 95 was 1.09 Jig/ml.7 Our earlier Pc bolus and irifusion study? used an initial dose of 0.0625 mg/kg and an infusion rate of 0.35 Jig/kg/min, and resulted in a steady state CPS2 of 0.21 Jig/ml, measured at a stimulus frequency of 0.2 Hz.
Calculation of relaxant dosage in normal patients by using averaged pharmacokinetic parameters
Dose response curves for dTc and Pc have been constructed in man from data obtained during anaesthesia which did not involve potent inhalation agents. 1O ,16,30,31 Table 6 , and these are marginally higher than those reported for studies involving stimulation frequencies of 0.1 Hz. This is due in part to calculation with V d~ rather than a smaller volume of distribution. The ratio of the bolus doses (dTc/Pc) given in Table 6 is in agreement with the early relative potency ratio of 7.4 reported by Miller and Eger, 11 respectively reducing the early potency ratio to 4.0. This is consistent with the findings of Lund and Stovner 32 who reported a steeper doseresponse curve for Pc than for dTc.
The infusion rates predicted by Equation 4 for maintenance of deep block in Table 6 give a late relative potency of 5.8. Despite considerable differences in technique between the two methods, this is comparable with the ratio of 5.1 found by Miller and Eger. ll The hourly dTc requirement shown in Table 6 falls in the 10 to 15 mg range described by Ryan 33 in 1964 .
Prediction of degree of paralysis
Combination of the data presented in Tables 1 and 6 and use of equation 2 allows prediction of intensities following single or multiple doses of the relaxants. The parameters given in Table  6 for the sigmoid curve plasma concentrationeffect relationships describe the curves derived for a stimulus frequency of 0.1 Hz, but most previous studies have used more rapid rates of stimulation, usually 0.2 to 0.3 Hz. To correct for the different stimulation rates the size of the dose in equation 2 should be proportionately increased. Thus the simulated response-time curves for 0.02, 0.04 and 0.08 mg/kg of Pc in Figure 1 are to the left of those of Kati 4 and of d'Hollander et al. 35 Their curves are presumably to the right of the predicted curves which might have resulted with use of a lower stimulus frequency. Equation 2 allows an assessment of cumulation of the relaxant to be made, i.e., the degree to which a second injection of a given dose will have a greater effect than the initial injection ( Table 7) . The results of a study by Walts and Dillon in 1968 are also included for comparison. 36 However, as their study involved the use of a Block-Aid Monitor operated at 0.25 Hz, their results with a dose of 8 mg/M2 of dTc cannot be compared directly with our own data even at the same dose level. Figure 2 is a graphical representation of dTc data included in Table 7 , when the effect from the initial dose (D l ) of 0.4 mg/kg had recovered to 90 per cent paralysis (Xl)' If then a second dose of 0.2 mg/kg was added (Dl + 0.5 D l ) recovery to 90 per cent paralysis again took a further time (~). Addition of incremental doses of the same size or of fractions thereof at the time of 50010 paralysis produced curves marginally to the right of those shown in Figure 2 . Conversely, when the same total dose is used as a single bolus, e.g. 1.5 D, or 2.0 D, these curves are slightly to the left of those shown. Walts and Dillon pointed out that their results have clinical importance to the practising anaesthetist. Once the duration of the initial dose of relaxant has been determined, the size of the subsequent dose could then be ascertained according to the anticipated course of surgery and the present intensity of blockade. Given use of the train-of-four technique, their comments are even more relevant today, provided the pharmacokinetics are normal. 
Changes in dose requirements and effects of relaxants with disease states
Muscle relaxant activity may alter under the influence of a variety of factors. Altered physiology, e.g. hypothermia, neuromuscular disorders, e.g. myasthenia gravis, or drugs interfering with neuromuscular transmission may all affect the intensity of paralysis observed in the patient. In all the above circumstances the primary change is in the sensitivity of the neuromuscular transmission process to a particular amount of drug.
In contrast, diseases impairing renal or hepatic function would appear to affect drug disposition without altering the plasma concentrations required for neuromuscular blockade. J7 , 38 The size of the initial bolus dose and hence the effects of the relaxant are related to its apparent volume of distribution (Vd, see equation 3). If this were reduced for exa~ple, by haemorrhagic shock 39 then the plasma concentrations would remain high prolonging the duration of activity. In contrast in patients with liver cirrhosis the value for Vd for Pc is
quatlOn 3 would then predict a bolus dose of Pc of 0.11 mg/kg, using the value of Vd~ of 416 mllkg found by the above workers, to achieve 95 per cent paralysis in such patients. The anaesthetist administering doses smaller than this might then observe "resistance" to Pc until this dose had been reached. However, thereafter the effects of the reduced plasma clearance in these patients would predominate,40 and the patients would then demonstrate "sensitivity" to the drug. Some patients in terminal renal failure demonstrate similar combined changes. 41 ,42 The plasma clearance of Pc is reduced in the presence of renal failure, total biliary obstruction and hepatic cirrhosis. 37 ,39,41 Olivero et al. 43 administered Pc by infusion to seven patients in their management of acute respiratory failure, and in whom acute renal failure co-existed. Their infusion rate varied from 1.3 to 3.1 mg per 70 kg per hour (compare Table 6 ), but this gave averaged Pc plasma concentrations between 0.4 and 1.0 I1g/ml. Gibaldi et al. 47 used their pharmacokinetic model to rationalise observations concerning the duration of blockade with dTc. Using a reduced plasma clearance in the absence of renal function, they predicted that there would be little effect on the duration of action of relatively small single doses of dTc but that the duration of large or multiple doses would be prolonged significantly.
Miller et al. 44 investigated three dose levels of Pc and reported that the time from administration to return of the twitch height to 95 per cent paralysis was approximately 20 min. longer in patients with renal failure than it was in patients with normal renal function. When d'Hollander et al. 35 made a similar comparative evaluation they did not confirm this difference at 90 per cent paralysis. They reported that prolongation of action becomes significant at 25 per cent paralysis following an initial Pc d?se of 0.04 mg/kg, and at 50 per cent paralysis With 0.08 mg/kg. The points for their latter dosage regimen are superimposed on the plot shown in Figure 3 which represents computer predicted response-time curves for dTc and Pc in patients with renal failure. Reference to figure 3 suggests that, for patients with renal failure, a dose of dTc of 0.4 mg/kg is equivalent to a dose of Pc of 0.07 mg/kg. The predictions made for average patients with disease states are based on data which has an even greater spread than those for normal patients recognising that the latter show considerable intersubject differences in the pharmacokinetics of the muscle relaxants. Combining this with another composite relationship, the plasma concentration response curve, introduces the likelihood of further inaccuracies when predicting precisely for any particular subject. However, knowledge of average pharmacokinetic and paralysis data and the likely influence of some disease states permits the anaesthetist to select initially a dosage regime which could be suitable for the patient, one to be modified later as required. Table 7 ), and the time at which recovery to 90070 paralysis is predicted is marked X,. The other two curves represent recovery from incremental doses given at this time, using amounts the same as (0, + 1.00,) or half (0, + 0.5 0,) the initial dose (0,). The interval until paralysis again reaches 900/0 is designated X, (see Table 7 ). 
